Aoxing Pharmaceutical Company, Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended Sept. 30, 2016
November 13, 2016
Share
Aoxing Pharmaceutical Company, Inc. announced unaudited consolidated earnings results for first quarter ended Sept. 30, 2016. For the quarter, the company reported sales of $7,569,296,000, income from operations of $1,703,506,000, income before income tax of $1,042,834,000, net income of $391,757,000, income attributable to shareholders of the company of $346,080,000, compared to the sales of $8,744,822,000, income from operations of $3,139,203,000, income before income tax of $2,292,236,000, net income of $1,348,433,000, income attributable to shareholders of the company of $1,267,936,000, basic and diluted loss per common share of $0.02,000 for the same quarter a year ago.
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotic, pain-management and addiction treatment pharmaceutical products. The Company holds approximately 140 drug production certificates covering narcotic pain-management, prescription medicines, over-the-counter (OTC) and active pharmaceutical ingredient (API) products. Its products include prescription drugs, such as Tilidine hydrochloride, Zhongtong'an and Humifuse Euphorbia Herb Tablet, and OTC drugs, such as Shanmei Capsule, Shaoshang Tincture, Yiqi Qiangshen Granule, Xiaopiling Granule, Xiongjushangqing Tablet, Juyuansuanbijia Oral Solutions, Longdanxiegan Tablet, Fenka Tablet, Shujinhuoxue Tablet, Fuketiaojing Tablet, Qingnao Jiangya Tablet, Yuanhu Pain Management Tablet, Bushenqiangshen Tablet, Baiziyangxin Pill, Qingguo Pill, Liuweidihuang Pill, Zhibaidihuang Pill, Xiaoyao Pill and Tianwangbuxin Pill.
AOXING PHARMACEUTICAL COMPANY, INC. 
